文献速递浆细胞疾病造血干细胞移植与细胞治疗

Cesni-cel(ARI0002h)治疗伴浆细胞白血病或中枢神经系统受累的超高危多发性骨髓瘤

Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.
PubMed 文献 · Br J Haematol · 2026-06-04

结果显示总缓解率88%,中位无进展生存期10.5个月,总生存期15.9个月,支持将PCL和CNS-MM纳入临床试验。

要点

  • Cesni-cel在伴PCL/CNS-MM的超高危骨髓瘤中总缓解率88%,≥VGPR率87%。
  • 中位PFS 10.5个月,中位OS 15.9个月。
  • 细胞因子释放综合征发生率76%(无≥G3),ICANS 1例G3,IEC-HS 18%(1例致死)。

核心结论

  • ARI0002h在复发超高危多发性骨髓瘤中诱导深度缓解,支持将PCL和CNS-MM纳入临床试验。

研究设计与样本

  • PCL按IMWG 2021标准定义;CNS-MM定义为软脑膜和/或脑实质受累。

主要发现

  • 74%具有高危细胞遗传学;中位既往治疗线数3;74%曾接受HSCT;2例既往BCMA暴露。
  • 17例(89%)接受ARI0002h;CRS发生率76%(无≥G3),G3 ICANS 1例(非CNS-MM),IEC-HS 18%(1例致死)。
  • 第+100天ORR 88%,其中87%达≥VGPR,80%达完全CNS缓解。
  • 中位PFS 10.5个月,中位OS 15.9个月。

关键数值与推荐

  • PCL定义依据IMWG 2021标准;CNS-MM依据软脑膜和/或脑实质受累。

临床怎么用

  • ARI0002h可作为伴PCL/CNS-MM的超高危多发性骨髓瘤患者的治疗选择,需关注IEC-HS等毒性。
  • 研究结果支持将PCL和CNS-MM患者纳入CAR-T临床试验。

局限性

  • 1例在单采前死亡,1例在生产期间死亡,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ultra-high-risk multiple myeloma (uHRMM), defined by extra-medullary disease (EMD, including central nervous system [CNS] or plasma cell leukaemia [PCL]), remains as a predictor of early relapse after chimeric antigen receptor T cell (CAR-T) therapy. We analysed the characteristics, toxicities, response and survival of patients with PCL/CNS-multiple myeloma (MM) treated with cesnicabtagene autoleucel (ARI0002h) at three Spanish centres (2020-2025). PCL was defined as per International Myeloma Working Group (IMWG) 2021 criteria; CNS-MM by leptomeningeal and/or intraparenchymal involvement. Nineteen patients (68% female; median age 61) were included: 12 patients had PCL, 5 had CNS-MM, and 2 had dual involvement. Fifty per cent had primary PCL. In CNS-MM, all had leptomeningeal disease and one had also intraparenchymal lesions. Fifty-seven per cent received CNS-directed therapy. Seventy four per cent harboured high-risk cytogenetics. Median prior lines: 3; 74% had haematopoietic stem cell transplantation (HSCT); two had prior B-cell maturation antigen (BCMA) exposure. One patient died pre-apheresis and one during manufacturing; 17 (89%) received ARI0002h. Cytokine release syndrome (CRS) occurred in 76% (none ≥G3), G3 immune effector cell (IEC)-associated neurotoxicity syndrome (ICANS) occurred in one case (not CNS-MM) and IEC-associated haemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) occurred in 18% (one fatal). Overall response rate (ORR) was 88% at day +100, of which 87% achieved ≥ very good partial response (VGPR) and 80% complete CNS response. Median progression-free survival (PFS) and overall survival (OS) were 10.5 and 15.9 months respectively. ARI0002h induces deep responses in relapsed uHRMM, supporting inclusion of PCL and CNS-MM in clinical trials.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jimenez-Mira C, Tovar N, Martínez-Cibrián N, et al. Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement. Br J Haematol. 2026. PMID: 42237881. doi:10.1111/bjh.70586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。